Search results for "allergic"

showing 10 items of 307 documents

Exhaled nitric oxide is associated with cyclic changes in sexual hormones

2013

Abstract Background We hypothesized that changes in the levels of sexual hormones during the menstrual cycle influence the concentration of nitric oxide in the exhaled air (FeNO) and alveolar exhaled nitric oxide (CANO). Methods Twelve healthy, non allergic women in their reproductive age (age range 25–37 years) were recruited. Subjects were studied, on alternate days, over the course of their menstrual cycle. At each visit, measurements of FeNO and CANO were performed. Progesterone and 17-β-estradiol concentrations were measured in salivary samples. Results Eight subjects completed the study. The levels of FeNO and CANO were 13 ± 4.7 pbb and 3.5 ± 1.9 pbb, respectively (mean ± SD). The mea…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedia_common.quotation_subjectReproductive ageBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideNitric oxidechemistry.chemical_compoundsexual hormonesInternal medicinemedicineHumansPharmacology (medical)SalivaGeneralized estimating equationMenstrual cycleMenstrual CycleProgesteronemedia_commonEstradiolbusiness.industryBiochemistry (medical)GenderBiomarkerHormonesSexual hormonesPulmonary AlveoliEndocrinologychemistryBreath TestsNon allergicExhaled nitric oxideAirway inflammation; Biomarker; Gender; Hormones; Adult; Breath Tests; Bronchi; Estradiol; Female; Humans; Menstrual Cycle; Nitric Oxide; Progesterone; Pulmonary Alveoli; Saliva; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)FemalebusinessHormoneAirway inflammation
researchProduct

Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

2016

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone …

Adultmedicine.medical_specialtyHydrocarbons Fluorinatedintranasal corticosteroidmedicine.drug_classmedicine.medical_treatmentImmunologynasal sprayAnti-asthmatic AgentMedication Adherence03 medical and health sciencesnasal aerosol0302 clinical medicineQuality of lifeNasal AerosolmedicineAnimalsHumansImmunology and AllergyAnti-Asthmatic AgentsChild030223 otorhinolaryngologyintranasal corticosteroidsAsthmaallergic rhinitisbusiness.industryRespiratory diseaseBeclomethasoneNasal Spraysasthmamedicine.diseaseRhinitis AllergicDermatologyBeclomethasone dipropionate hydrofluoroalkaneAerosol Propellants030228 respiratory systemNasal sprayinflammationQuality of LifeCorticosteroidNasal administrationbusinessallergic rhiniti
researchProduct

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

2017

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The …

AgingProcess managementGeriatrics & GerontologyEuropean Innovation Partnership on Active and Healthy Ageing polypharmacy education falls frailty integrated care citizen empowerment chronic respiratory diseasesHealth BehaviorChronic respiratory diseasesPARTNERSHIPCoaching[SHS]Humanities and Social Sciences0302 clinical medicineSurveys and Questionnaires80 and overMedicineCooperative BehaviorComputingMilieux_MISCELLANEOUSInterventionsmedia_commonintegrated careAged 80 and over:Enginyeria biomèdica [Àrees temàtiques de la UPC]Multiple Chronic ConditionOrganizational Innovation3. Good healthCHRONIC RESPIRATORY-DISEASESHealthAction planGeneral partnershipFallsHEALTHPartnershipINTERVENTIONSHumanmedia_common.quotation_subjectfallFrail ElderlyEuropean Continental Ancestry GroupBioengineeringWhite PeopleEducation03 medical and health sciencesEUROPEAN-UNIONActive and Healthy Ageingmedia_common.cataloged_instanceHumansBioenginyeriaEuropean unionAgedScience & TechnologyNutrition & DieteticsPreventionPREVENTIONCitizen empowerment030228 respiratory systemAction (philosophy)European Innovation Partnership on Active and Healthy Ageing; polypharmacy; education; falls; frailty; integrated care; citizen empowerment; chronic respiratory diseases; Accidental Falls; Aged; Aged 80 and over; Chronic Disease; Cooperative Behavior; Europe; Frail Elderly; Humans; Multiple Chronic Conditions; Organizational Innovation; Polypharmacy; Surveys and Questionnaires; Aging; European Continental Ancestry Group; Health BehaviorGeriatrics and GerontologyGerontologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]OPERATIONAL DEFINITIONEMPOWERMENTMedicine (miscellaneous)Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyChronic respiratory-diseasesAllergic rhinitisQUALITY-OF-LIFEEuropean-UnionNutrition and DieteticSurveys and Questionnaire030212 general & internal medicineMultiple Chronic ConditionsEmpowermenteducationNutrition and DieteticsFrailtyAccidental FallIntegrated careALLERGIC RHINITISEuropeSettore MED/42EmpowermentLife Sciences & BiomedicinefrailtyEuropean Innovation Partnership on Active and Healthy AgeingJournal ArticleMETIS-318216IR-101708Responsible Research and Innovationbusiness.industrychronic respiratory diseaseIntegrated careOperational definition3121 General medicine internal medicine and other clinical medicineChronic DiseasePolypharmacycitizen empowermentAccidental Fallschronic respiratory diseases; citizen empowerment; education; European Innovation Partnership on Active and Healthy Ageing; falls; frailty; integrated care; polypharmacy; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyQuality-of-lifebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe journal of nutrition, healthaging
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

EAACI Position paper on the standardization of nasal allergen challenges.

2018

DR. FARID, S.H. M.H. M. Kn. - FR FARID/0000-0003-0372-4963; Gevaert, Philippe/0000-0002-1629-8468; Hox, Valerie/0000-0003-2390-294X; Wagenman, Martin/0000-0002-9734-0241; Vent, Julia/0000-0001-5071-9580 WOS: 000438710600002 PubMed: 29377177 Nasal allergen challenge (NAC) is an important tool to diagnose allergic rhinitis. In daily clinical routine, experimentally, or when measuring therapeutic success clinically, nasal allergen challenge is fundamental. It is further one of the key diagnostic tools when initiating specific allergen immunotherapy. So far, national recommendations offered guidance on its execution; however, international divergence left many questions unanswered. These differ…

Allergen immunotherapymedicine.medical_specialtyNasal Provocation TestsStandardizationImmunologyAdvisory CommitteesAftercareallerginen nuhaDiagnostic toolsmedicine.disease_causeSneezingdiagnostic toolsUnmet needsAllergen challenge03 medical and health sciences0302 clinical medicineAllergennasal provocation testGermanyotorhinolaryngologic diseasesImmunology and AllergyMedicineHumans030223 otorhinolaryngologyIntensive care medicineAnaphylaxisAdministration IntranasalSkin TestsProtocol (science)allergic rhinitisbusiness.industryaltistuskoePruritusNasal Spraysrespiratory systemAllergensImmunoglobulin ERhinitis Allergicta3125Nasal Mucosa030228 respiratory systemPosition paperNasal Obstructionnasal allergen challengebusinessAllergy
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

Interruption of CD28-mediated costimulation during allergen challenge protects mice from allergic airway disease

2012

Background Allergic asthma is a T H 2-promoted hyperreactivity with an immediate, IgE, and mast cell–dependent response followed by eosinophil-dominated inflammation and airway obstruction. Objective Because costimulation by CD28 is essential for T H 2 but not T H 1 responses, we investigated the effect of selective interference with this pathway in mice using the models of ovalbumin and house dust mite–induced airway inflammation. Methods To study the role of CD28 in the effector phase of allergic airway inflammation, we developed an inducibly CD28-deleting mouse strain or alternatively used a CD28 ligand-binding site–specific mouse anti-mouse mAb blocking CD28 engagement. Results We show …

Allergic asthmaLymphocyte ActivationImmunoglobulin Emedicine.disease_causeT-Lymphocytes RegulatoryMice0302 clinical medicineAirway resistanceAllergenImmunology and AllergySensitizationMice Inbred BALB C0303 health sciencesbiologyAntibodies Monoclonalovalbuminrespiratory system3. Good healthmedicine.anatomical_structurecostimulationconditional CD28 knockout miceFemalemedicine.symptomImmunologyInflammation03 medical and health sciencesTh2 CellsCD28 AntigensRespiratory HypersensitivitymedicineAnimalsHumansAntigens DermatophagoidesLymphocyte CountAntibodies Blocking030304 developmental biologyHouse dust miteCD28-specific mAbbusiness.industryReceptor Cross-TalkAirway obstructionmedicine.diseasebiology.organism_classificationMice Mutant Strainsrespiratory tract diseasesDisease Models AnimalCTLA-4Immunologybiology.proteinbusiness030215 immunology
researchProduct

Allergic contact dermatitis with contact urticaria to colophony from an alternative remedy.

2012

Allergic contact dermatitialternative remedySettore MED/35 - Malattie Cutanee E Venereecolophonycontact urticaria
researchProduct